The Tokyo-based company, which is also known under Advanced Center for Tissue Engineering Ltd. (ACTE) and an affiliate to the IMS group, which runs a number of hospitals in Japan, has established a national system to collect baby teeth and permanent teeth such as wisdom teeth, with a patented technology to prevent drying of the pulps. The pulp tissue is saved and the mesenchymal stem cells are cultured. HLA typing showed a match to about 70 % of all Japanese. By 2018, it is expected to cover 90 %. The cells can be used for the treatment of dental diseases, but wider applications are also being explored.

White Cross website, https://www.whitecross.co.jp/organizations/view/16